17 October 2025 - Brinsupri was reviewed under CHMP's accelerated assessment pathway as it is considered of major interest for public health and therapeutic innovation.

Insmed today announced that the CHMP of the EMA has adopted a positive opinion recommending approval of its DPP1 inhibitor Brinsupri (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

Read Insmed press release